Long-Term Pioglitazone Treatment Has No Significant Impact on Microglial Activation and Tau Pathology in P301S Mice

Autor: Lea Helena Kunze, François Ruch, Gloria Biechele, Florian Eckenweber, Karin Wind-Mark, Lina Dinkel, Paul Feyen, Peter Bartenstein, Sibylle Ziegler, Lars Paeger, Sabina Tahirovic, Jochen Herms, Matthias Brendel

Publikováno v: International journal of molecular sciences 24(12), 10106 (2023). doi:10.3390/ijms241210106 special issue: "Neuroinflammation in the Pathogenesis of Alzheimer's Disease and Related Dementias"

Neuroinflammation is one disease hallmark on the road to neurodegeneration in primary tauopathies. Thus, immunomodulation might be a suitable treatment strategy to delay or even prevent the occurrence of symptoms and thus relieve the burden for patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06be329f01c713eaa223140ce31a0479
https://doi.org/10.20944/preprints202304.1153.v1

Dual PPARα/γ agonist aleglitazar confers stroke protection in a model of mild focal brain ischemia in mice

Autor: Golo Kronenberg, Stephanie Wegner, Matthew Blake Wright, Matthias Endres, Ria Uhlemann, Valérie Boujon, Karen Gertz, Ulrich Laufs

Publikováno v: Journal of molecular medicine 97(8), 1127-1138 (2019). doi:10.1007/s00109-019-01801-0
Journal of Molecular Medicine (Berlin, Germany)

Peroxisome proliferator-activated receptors (PPARs) control the expression of genes involved in glucose homeostasis, lipid metabolism, inflammation, and cell differentiation. Here, we analyzed the effects of aleglitazar, a dual PPARα and PPARγ agon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f167de9aa317b1f36be7747dd6383118
https://pub.dzne.de/record/140815